Stocks Health care NKTX
NASDAQ · Health careNkarta, Inc. (NKTX)
It posted a net loss of $128.9M. In fiscal 2025 capital spending exceeded operating cash flow by $89.9M. At September 30, 2026 it held $48.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Nkarta, Inc.
- Net worth
- Nkarta, Inc. has a market value (market cap) of $113.9M at the latest share price, and shareholders' equity of $215.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $104.1M.
- Cash flow
- In fiscal 2025 operations used $88.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Nkarta, Inc.'s next report is expected around March 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Nkarta, Inc. does
Nkarta, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NKTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$104.1M | -$1.41 | -$89.9M |
| 2024 | $0 | -$108.8M | -$1.60 | -$104.1M |
| 2023 | n/a | -$117.5M | -$2.40 | -$114.3M |
| 2022 | n/a | -$113.8M | -$2.61 | -$104.1M |
| 2021 | n/a | -$86.1M | -$2.62 | -$73M |
| 2020 | n/a | -$91.4M | -$5.44 | -$51M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Nkarta, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 6, 2026
- November 5, 2026
- November 5, 2026
- August 10, 2026
- August 10, 2026
- June 11, 2026
- May 19, 2026Activist stake changed SCHEDULE 13D/A
- May 12, 2026
- May 12, 2026
Insider trades
What the people running Nkarta, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 18, 2026 | Hastings Paul JChief Executive Officer, Director | Sold | 1,776 | $4.8K |
| January 15, 2026 | Mahmood NadirPresident | Sold | 5,649 | $11.7K |
| January 15, 2026 | Hastings Paul JChief Executive Officer, Director | Sold | 26,046 | $53.9K |
| January 6, 2026 | Hastings Paul JChief Executive Officer, Director | Received as pay | 94,000 | - |
| January 6, 2026 | Mahmood NadirPresident | Received as pay | 80,000 | - |
| January 6, 2026 | Rose Shawn MarshallSee Remarks | Received as pay | 70,000 | - |
Who owns NKTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 18.9% | March 29, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 136 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 10,805,129 | 0 |
| BlackRock, Inc. | 6,300,212 | +1,791,739 |
| NEA Management Company, LLC | 3,568,781 | 0 |
| Samsara Biocapital, LLC | 3,507,666 | 0 |
| SR One Capital Management, LP | 3,333,333 | 0 |
| GSK plc | 3,150,732 | 0 |
| Monaco Asset Management SAM | 2,373,400 | -148,532 |
| Vanguard Capital Management LLC | 2,226,415 | +214,994 |
| Citadel Advisors LLC | 2,174,745 | +390,751 |
| Two Sigma Investments, LP | 1,873,293 | -174,083 |
| Wasatch Advisors LP | 1,577,847 | 0 |
| State Street Corp | 1,286,109 | +48,635 |
| Geode Capital Management, LLC | 1,285,507 | +17,592 |
| Renaissance Technologies LLC | 1,177,652 | -554,720 |
| Aqr Capital Management LLC | 1,054,251 | +458,525 |
| AWM Investment Company, Inc. | 906,000 | 0 |
| Blackstone Inc. | 747,044 | new |
| Marshall Wace, Llp | 673,010 | new |
| Panagora Asset Management Inc | 583,249 | +299,039 |
| Jpmorgan Chase & Co | 562,980 | -12,021 |
Insiders
3 insiders reported holding 627,974 shares in total, about $998.5K at the last price.
| Holder | Shares |
|---|---|
| Hastings Paul JChief Executive Officer, Director | 390,247 |
| Mahmood NadirPresident | 167,727 |
| Rose Shawn MarshallSee Remarks | 70,000 |
Questions about NKTX
What does Nkarta, Inc. do?
Nkarta, Inc. is a company in the Health care sector, listed on NASDAQ as NKTX. Its shares trade on NASDAQ under the ticker NKTX.
What is Nkarta, Inc.'s net worth?
Nkarta, Inc. has a market value (market cap) of $113.9M at the latest share price, and shareholders' equity of $215.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Nkarta, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $128.9M.
When did Nkarta, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the investor disclosure from November 9, 2026.
When is Nkarta, Inc.'s next earnings report?
Nkarta, Inc.'s next report is expected around March 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NKTX with
Follow NKTX
Get an email when Nkarta, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Nkarta, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.